Thursday, February 7, 2013

• Alnylam Pharma's 4Q loss widens on settlement costAP (Thu, Feb 7)
• ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Results of OperatioEDGAR Online (Thu, Feb 7)
• Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial ResultsBusiness Wire (Thu, Feb 7)

Tuesday, February 5, 2013

• Alnylam-MDCO Join for ALN-PCSZacks (Tue, Feb 5)
• Alnylam to Webcast Presentation at Upcoming Investor ConferencesBusiness Wire (Tue, Feb 5)
• Alynylam stock up on The Medicine Company’s $25M betat bizjournals.com (Tue, Feb 5)
• Over 25 Companies to Present at Emerald Groundhog Day Investment ForumBusiness Wire (Tue, Feb 5)

Monday, February 4, 2013

• A Cholesterol-Treatment Contender Partners Upat Motley Fool (Mon, Feb 4)
• Medicines Company Braces For 2015 With Alnylam PCSK9 Dealat Seeking Alpha (Mon, Feb 4)
• ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online (Mon, Feb 4)
• 4 Healthcare Stock Stories to Treat the Monday Bluesat Wall St. Cheat Sheet (Mon, Feb 4)
• The Medicines Company Licenses Alnylam's Cholesterol Programat Motley Fool (Mon, Feb 4)
• Medicines Co, Alnylam Pharma enter allianceAP (Mon, Feb 4)
• The Medicines Co., Alnylam form strategic alliance to develop RNAi Therapeuticstheflyonthewall.com (Mon, Feb 4)
• The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of HypercholesterolemiaBusiness Wire (Mon, Feb 4)

Friday, February 1, 2013

• Isis: FDA Approval Of Kynamro Promises A Bright Future For Companyat Seeking Alpha (Fri, Feb 1)
• With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watchat Seeking Alpha (Fri, Feb 1)

Thursday, January 31, 2013

• Alnylam's ALN-VSP Data PublishedZacks (Thu, Jan 31)
• Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2012 Financial ResultsBusiness Wire (Thu, Jan 31)

Wednesday, January 30, 2013

• Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver CancerBusiness Wire (Wed, Jan 30)

Tuesday, January 29, 2013

• Prognosis Positive: Medical Growth Stocks to Watchat Motley Fool (Tue, Jan 29)
• Boston-area biotech stocks raise $1B in stock offeringsat bizjournals.com (Tue, Jan 29)

Monday, January 28, 2013

• CEO: Alnylam isn’t eyeing an acquisition, despite $400M in cashat bizjournals.com (Mon, Jan 28)

Thursday, January 24, 2013

• ARIAD prices $300M stock offering to support launch of leukemia drugat bizjournals.com (Thu, Jan 24)
• Alnylam: Rally On No News Leaves Room For Downsideat Seeking Alpha (Thu, Jan 24)

Add ALNY News to My Yahoo!